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Abstract
The purpose of this study was to examine sex-specific differences in the blood
glucose (BG) response to recurrent aerobic exercise in type 1 diabetes. Specifically, we
examined the role of peak estrogen (E2) concentrations during proestrus on BG response to
prolonged aerobic exercise. To do so, nineteen Sprague-Dawley rats were assigned to four
exercised groups: control female (CXF; n = 5), control male (CXM; n = 5), diabetic female
(DXF, n = 5) and diabetic male (DXM, n = 4). Diabetes was induced in DX groups via
subcutaneous injection of low dose streptozotocin. After four days of exercise, liver glycogen
and BG responses were compared. The final bout of exercise took place during proestrus
when estrogen concentrations were at their highest in the female rats. No liver glycogen
differences between DXF and DXM or CXF and CXM were evident. During days 1-3, DXF
had lower BG concentrations during exercise, but quicker BG recovery than DXM.
Therefore, fluctuating estrogen concentrations may have reduced the sex based differences in
BG response and fuel selection during exercise.
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Summary for Lay Audience
Type 1 diabetes mellitus (T1DM) is a disease that results in the body being unable to
produce a hormone called insulin, which helps to control blood sugar levels. There is no
singular cause of T1DM, and there is no known cure. Treatment of this disease includes
insulin administration either by pump or injection to maintain blood sugar near normal levels.
Diet and exercise can assist in the management of this disease; however, aerobic exercise,
which is moderate or high intensity in nature for a prolonged period of time, can result in low
blood sugar, or hypoglycemia. During aerobic exercise the body uses a combination of sugar
(glucose) and fat as fuel, and for a person with T1DM it would be more beneficial to utilize
primarily fat as a fuel source in order to maintain blood sugar. The primary female sex
hormone estrogen has been shown to increase the usage of fat and spare the usage of glucose.
The level of estrogen fluctuates throughout the menstrual cycle and is considerably higher
during the luteal phase of the cycle, which accounts for half of the cycle length. It is possible
that due to the higher estrogen levels during this phase of menstruation females with T1DM
may be more likely to use fat than sugar during aerobic exercise, protecting them against
exercise induced hypoglycemia to a greater degree than males with T1DM. In this thesis we
studied four rodent groups: diabetic males, diabetic females, nondiabetic males and
nondiabetic females. All animals underwent four consecutive days of aerobic exercise
training. Vaginal cytology was used to determine the cycle length and pattern in the rats, and
the female rats were staged so that the final day of exercise took place during the phase with
the highest estrogen levels (proestrus). Liver samples were taken on the final day of exercise
to elucidate and glycogen sparing effect. The primary findings of this study was that the
diabetic females recovered from exercise faster than the diabetic males. We did not find a
glycogen sparing effect between the diabetic males and the diabetic females; however, both
iii

the diabetic males and females had significantly less liver glycogen than their non-diabetic
counterparts by the end of the four day protocol. These findings indicate that there is less
risk of hypoglycemia to the T1DM female during recurrent aerobic exercise when estrogen
levels are high, but no protective effect against liver glycogen depletion.
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Chapter 1

1.1 Overview of Type 1 Diabetes Mellitus
Diabetes is a category of diseases that is characterized by the body’s inability to
produce or utilize insulin efficiently. Type 1 and type 2 diabetes mellitus are the two
main types of diabetes, with the incidence of type 1 staying slowly increasing overtime
and accounting for approximately 10% of diabetes diagnoses in Canada1. In type 2
diabetes mellitus (T2DM) a combination of lifestyle, environmental and genetic factors
result in chronic hyperglycemia leading to hyperinsulinemia and insulin resistance 2, 3. As
a result glucose metabolism is disrupted, and many cells are unable to use glucose from
the blood stream. Chronic hyperglycemia and increased free fatty acids (FFA) cause
oxidative stress to the -cells of the pancreas, worsening the state of hyperglycemia 4,5.
T2DM accounts for approximately 90% of all cases of diabetes and is more common in
developed or industrialized countries 6,7. The global prevalence of diabetes is expected to
rise to 10.5% by 2040, and the increase is expected to be due to an increase in T2DM
cases7. Although there are severe comorbidities associated with T2DM, the symptoms
can be largely managed through diet and exercise modifications if caught early, and
several antihyperglycemic agents are available8. Majority of individuals diagnosed with
T1DM are diagnosed prior to the age of 20, whereas T2DM is diagnosed more often in
adults although diagnoses in younger individuals are becoming more common5.
The pathophysiology of type 1 diabetes mellitus (T1DM) is an entirely separate
process than that of T2DM, in that the -cells of the pancreas are destroyed in an
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autoimmune cytokine-mediated reaction such that the pancreas can no longer produce
sufficient amounts of insulin 4,9. The disruption of the pancreatic -cells is accompanied
by -cell disruption, resulting in elevated glucagon levels which further disrupts glucose
homeostasis 5,10. Glucagon is an important metabolic hormone released by the -cells of
the pancreas in response to hypoglycemia onset (lowered blood glucose) to raise BG
through glycogenolysis to increase BG, and in periods of hyperglycemia glucagon
expression is suppressed. This suppression of glucagon is disrupted in T1DM, resulting in
no reduction in glucagon levels during periods of hyperglycemia which can further
increase BG levels10. The state of hyperglycemia is further worsened by the usage and
availability of free fatty acids (FFAs), which are metabolized by the liver into ketone
bodies10. When ketone body production exceeds the body’s ability to utilize them a
condition called ketoacidosis results and can be fatal, especially for children10,11. Prior to
the development of insulin therapy, T1DM was fatal usually within 1-2 years, due to
starvation, coma, and ketoacidosis12,13. The discovery of insulin meant the patient with
T1DM could utilize exogenous insulin to normalize glycemia. The initial results of this
new insulin treatment were temporary, and a continued dosage of insulin was required to
keep symptoms from resurfacing14. It was later discovered that complications of both
T1DM and the insulin treatment itself were common without precise control of dosage.
Retinopathy, nephropathy and cardiovascular complications are all linked to poor
glycemic control while taking insulin14-16. However, when administered properly the use
of insulin to treat T1DM has reduced mortality and increased life expectancy overall; the
common causes of mortality related to T1DM are now complications such as
cardiovascular disease rather than the historical 13.
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Further developments in the medical field culminated in the Diabetes Control and
Complications Trial, an extensive cohort study that examined the benefits of intensive
insulin therapy (IIT) compared to conventional therapy (CT)17. CT, a more traditional
approach to treatment consisted of one to two injections of insulin per day, with the goal
of preventing symptoms of hyperglycemia or causing hypoglycemia. IIT is a more
involved process, with multiple smaller doses of insulin throughout the day, which were
adjusted based on self-administered BG tests. Participants were also advised to alter their
insulin dosage based on exercise and diet17. The purpose of IIT is to maintain a consistent
BG (3.9 -6.7 mmol/L) level throughout the day, and a monthly hemoglobin A1c (HbA1c)
of less than 6%. The HbA1c is a measure of glycated hemoglobin, a process when a
component of one of the hemoglobin dimers (HbA) is exposed to a hyperglycemic
environment and this component becomes glycated19. The DCCT showed that
participants undergoing IIT had tighter glycemic control and lower HbA1c combined with
reductions in complications associated with diabetes than those undergoing CT17
Moreover, IIT decreased the risk and progression of retinopathy, reduced neuropathy and
nephropathy, but also caused a threefold increase in the risk of hypoglycemia compared
to the CT treatment17,18,20,21. Hypoglycemia is commonly described as a BG below
3.0mmol/L, however in diabetics a BG between 3.0-3.9 mmol/L is sufficient to require
intervention to avoid visual disturbance, headaches, loss of consciousness or seizures22.
Participants who experienced one bout of severe hypoglycemia were more likely to have
subsequent hypoglycemic episode. Lower HbA1c was also a predictor of hypoglycemia
but prior hypoglycemia was the strongest predictor. Interestingly, the relative risk of
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hypoglycemia between CT and IIT was greater for males than females, although this was
not a main discussion point in the studies18,20.

1.2 Cardiovascular benefits to aerobic exercise and
Exercise-Induced Hypoglycemia in T1DM patients
As noted above, IIT is used to modify the insulin dosage when performing
physical activity in order to avoid hypoglycemia by monitoring insulin dosage multiple
times throughout the day. Indeed, the fear of exercise related hypoglycemia is one of the
main non-physical barriers to exercise for type 1 diabetics21. Exercise is often prescribed
to patients with T1DM due to the well-known associated cardiovascular benefits22-24.
Therefore, a clear understanding of the potential risks that may be incurred during
exercise is essential to safely prescribe an exercise program in order to prevent postexercise or nocturnal hypoglycemia development22-24. For example, the type, duration,
intensity and modality of the exercise can impact the risk of hypoglycemia as the BG
response to the exercise is dependent upon multiple factors22,23. Aerobic exercise training
has been observed to reduce many of the complications often associated with moderate
hyperglycemia in insulin treated rodent models25. For example, insulin resistance is
improved in rodents that have undergone a 10-week long aerobic training program, likely
due to the insulin like effect of muscle contractions26. Muscle contraction causes GLUT4
transporters to move to the membrane of the muscle cell and increases the amount of
glucose that is taken into the cell, similar to the effects of insulin27. Failing to account for
this increase in glucose removal from the blood stream or failing to reduce insulin levels
prior to exercise can increase the risk of hypoglycemia. High-intensity aerobic exercise
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training has been shown to maintain parasympathetic function27,28 and cardiac
performance25 in insulin treated T1DM rats. T1DM is known to reduce autonomic control
of cardiac muscle, and aerobic exercise training may improve vagal control of heart
rate27. Aerobic training may also decrease insulin dosage requirements27,29. By the end of
a 10-week training program including high intensity or low intensity aerobic exercise,
insulin requirements were significantly reduced, and the high intensity aerobic exercise
resulted in the greatest reduction in insulin dosage27,29. Aerobic exercise also improves
lipid levels and cardiovascular fitness is improved, and all-cause mortality risk is
lowered24.
While the risk of hypoglycemia onset is evident across each mode of exercise
likely due to contraction mediated glucose uptake, decreased counterregulatory hormonal
response and failure or lack of knowledge to appropriately adjust insulin prior to
prolonged exercise22. Resistance exercise is associated with less of a decline in BG
response to exercise in comparison to aerobic exercise, likely due to the minimal effect
on reducing insulin requirement29. Although a decreased BG during the late recovery
period (four to six hours post exercise) or overnight, termed nocturnal hypoglycemia30,
might be more apparent with resistance exercise. Resistance exercise training has not
definitively been shown to improve HbA1c levels in T1DM but has shown improvement
in these levels for T2DM; however, HbA1c does not measure the other physical benefits
of resistance exercise such as increased strength29-31. Resistance exercise ultimately
presents lower risk of hypoglycemia, and benefits such as increased muscular strength,
bone density and ability to perform functional tasks are similar to those seen in nondiabetics24. Overall, a combination of both exercise and resistance training is beneficial to
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diabetics, and aerobic training may be the most beneficial in terms of reducing
comorbidities associated with T1DM so long as the appropriate measures such as insulin
reduction or carbohydrate loading are taken22,32. In fact, aerobic exercise training has
been shown to lead to greater CVD improvements than IIT, the standard treatment for
T1D99. These improvements in aerobic exercise-treatment animals were evident despite
the use of CT to minimize the risk of hypoglycemia during exercise.
The issue of exercise becomes more complex when examining athletes or avid
exercisers with T1DM who are required perform repetitive bouts of intense exercise two
or more days in a row, and sometimes multiple times a day. The effects of a single bout
of aerobic exercise may exacerbate the hypoglycemic onset during subsequent exercise,
particularly if that exercise is partaken during the extended recovery period when BG
levels may not be fully recovered35. During prolonged aerobic exercise there is a marked
increase in muscle glucose uptake, increased hepatic glucose release and
gluconeogenesis, rarely resulting in hypoglycemia under normal conditions in nondiabetic individuals35. In these healthy individuals, glucagon, catecholamines and cortisol
are secreted in response to acute exercise, resulting in availability of glucose for the
working muscle39. However, during subsequent exercise a decrease in metabolic and
neuroendocrine responses is evident in both diabetic and healthy subjects of both
sexes33,34.
The neuroendocrine response to exercise had been observed to be greater in
healthy males than healthy females, but only at moderate intensities36,37. Epinephrine,
norepinephrine and growth hormone (GH) for example are lower in females than in
males during hypoglycemia and periods of normal glycemia. It has been suggested that
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women have greater sensitivity to the actions of these hormones, resulting in lower
amount of hormone required to elicit the same response38. Antecedent periods of
hypoglycemic stress, either due to exercise or exogenous insulin correction, results in a
blunted neuroendocrine response in both sexes, but the blunting is more profound in
males and therefore the effects of hypoglycemia are more apparent in males38. The
glucagon response is lower following previous periods of hypoglycemia in both sexes but
is more severely inhibited in males34. There are many potential mechanisms that may
explain these sex mediated differences in the glycemic response to exercise; however, it
is believed that differences in the lipolytic metabolism is responsible. It is plausible that
women are protected against hypoglycemia development during acute or repetitive
exercise through a stronger reliance on fat metabolism and a reduction in muscle uptake
of glucose in comparison to men33,39.

1.3 The Glucoregulatory response to exercise
Prolonged exercise causes a disruption of the normal state of metabolism and in
turn the body takes actions against the potential development of hypoglycemia. While the
threshold of hypoglycemia where symptoms occur is around 3.0 mmol/L, any further
reduction in blood glucose below 3.8 mmol/L results in a counterregulatory response 41,42.
Epinephrine and glucagon are the first to be released, followed by growth hormone
release shortly after. Epinephrine and glucagon are signal molecules that initiate a
cascade of events to stimulate glycogenolysis in the muscle and liver. Below 3.5 mmol/L
cortisol is released, stimulating gluconeogenesis and suppressing glycogen synthesis43.
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Muscle cells decrease glucose uptake and adipose tissue is stimulated to increase
lipolysis, ensuring alternate forms of energy can supply the brain43. Each of these
hormones become critical when BG drops below physiologically normal levels and
although some studies have shown cortisol deficiency results in a significantly slower
return to resting BG levels, the presence of all hormones are required to protect and
correct hypoglycemia42,44,45. In response to aerobic exercise in non-diabetics, the
glucoregulatory response is greater in males; however, the sensitivity to the hormones
involved seems to be greater in females30. During exercise, hormonal release in females
may be lower, but the effects such as lipolysis are greater in females; moreover,
following prior hypoglycemia females are able to maintain a more adequate
glucoregulatory response than males33,34,38. The mechanism behind why diabetic females
maintain a glucoregulatory response to exercise is unclear, however it has been suggested
that the differences in sex hormones plays a role50,51.
Athletes or exercisers with T1DM show a different response to aerobic exercise
than non-diabetics. Due to the utilization of exogenous insulin, circulating insulin levels
are higher than non-diabetics40. The increased insulin level, even if reduced prior to
exercise, results in greater muscle uptake of glucose such that there is a drop in BG
during moderate aerobic exercise 22,32,46. The hormone response to acute exercise is
different in T1D than in non-diabetic males; however, these studies were conducted using
male rats so it is not clear if the same hormone changes would be present in females46.
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1.4 The Menstrual and Estrous Cycles
Due to naturally occurring hormone fluctuations, fewer exercise studies have
included the study of females. During the menstrual cycle, serum estradiol (E2),
progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) fluctuate
in a relatively predictable manner52. While the pattern of hormone cycling may be
similar, there can be significant variation in the level of these hormones between
individuals due to race, age or genetic variation53-55. Studies which do examine sex
differences in response to exercise are typically performed during the follicular phase
(FP) of the menstrual cycle as estrogen levels are at their lowest and most consistent
values, making analysis between the sexes simpler51. Some studies are further
complicated by the use of oral contraceptives which pharmaceutically inflate the estrogen
and/or progesterone levels and seemingly demonstrate that higher estrogen levels are
beneficial to training adaptations56,57. By limiting the influence of sex hormones on the
outcome these studies neglect half of the lifespan of sexually mature females.
The hormonal cycle which occurs in females can be described based on changes
within the uterus or the ovary and occur within the same time period. The follicular (FP),
ovulatory and luteal phases (LP) are part of the ovarian cycle, which is dictated by the
maturation of the follicle, oocyte release (ovulation), and formation of the corpus
luteum58. The FP is thirteen days long, ovulation is typically the 14th day, and the luteal
phase lasts approximately fourteen days. The uterine cycle is comprised of menstruation
(5 to 7 days), the proliferative phase, and the secretory phase (14 days). Menstruation
aligns with the start of the follicular phase and the degradation of the corpus luteum58.
For the purposes of this review, the FP and LP of the ovarian cycle were examined with
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regard to the hormones that are released during these phases. The ovarian (estrogen and
progesterone) and pituitary (LH and FSH) hormones are released in a cyclical manner
and are modulated by both positive and negative feedback loops52. During the luteal
phase (LP), E2 levels increase, and suppress the release of LH and to a lesser degree
FSH. Progesterone is also released from the corpus luteum, causing a surge in
progesterone levels as well. If there is no fertilization, the FP begins with the shedding of
the uterine lining. E2 levels are decreased, and FSH is released from the pituitary to aid in
the maturation of new follicles. As the follicle matures, E2 levels rise slowly, and
positive regulation of LH results in high LH levels. This increase in LH marks the
beginning of the LP52,59. While LH, FSH and progesterone levels influence multiple
pathways in the body, E2 is considered the most important in terms of its influence on
gene transcription and signaling cascades relating to metabolism. In particular, E2 has
been shown to regulate adipocyte metabolism52,59.
17 estradiol is the primary form of circulating E2 in humans. E2 exerts its
influence by binding to estrogen receptor alpha (ER), estrogen receptor beta (ER), or
G-protein coupled estrogen receptor (GP-ER). The uterus is the main E2 target, and
changes in the uterine lining can be observed and used to approximate E2 levels60,61. E2
is carried through the bloodstream into the cell, where it binds with ER or ER, which
exert effects on gene expression, notably in the liver and pancreas in addition to the
uterus61-63. E2 binding to either ER or ER cause the receptor to dissociate from
HSP90, a stabilization and chaperone protein, in the cytosol and translocate into the
nucleus where it binds to specific locations on the genome61. In the rat, the estrous cycle
is a four stage cycle that occurs over the course of 4-5 days and is equivalent to the
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menstrual cycle in humans60,69,70. Puberty occurs following the fourth post-natal week,
when the ovaries mature in response to increases in LH, and maturation is achieved 60
days postnatally60,71. There are substantially higher levels of E2 and progesterone
observed after 45 days, indicating maturity and that the reproductive cycle has
commenced71. It is widely recognized that estrogen levels are the lowest during estrus7274

and typically highest during proestrus 70,72,73,75. Metestrus and diestrus typically have

the highest levels of progesterone76 and are sometimes considered one phase or different
stages of the same phase60,77,78. Metestrus is usually the shortest stage and therefore it is
likely for this stages to be missed or to be in transition into diestrus60,69. Figure 1 presents
the differences between the relative concentrations of estrogen during the various phases
of the menstrual and estrous cycles. The highest estrogen concentrations occur over days
14-28 in the human, and within a 12 hour time frame in the rat.
In the liver, gene expression is altered over the four day estrus cycle in mice in
accordance with the level of estrogen present, and these changes are predominantly in
carbohydrate and lipid metabolism61,63. Elevated E2 levels during proestrus were
correlated with high mRNA and differing patterns of ER activation when compared to
lower E2 phases; these changes were evident within 24 hours suggesting that throughout
the four day cycle E2 changes exert both rapid and genetic effects63. GP-ERs are found
throughout the body, in the liver, islet cells of the pancreas, ovaries and adipose tissue
among others62,64,65. The binding of E2 to GP-ER results in an increase of cyclic AMP
(cAMP) and Ca2+ 61. E2 can have both rapid and genomic effects on the body, resulting in
daily differences in gene products and metabolic homeostasis. One genomic effect of E2
occurs within the pancreas. Insulin gene expression varies with estrus, with the greatest
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levels of insulin gene expression observed during proestrus when E2 levels are highest.
It has been reported that clinically high E2 levels may induce insulin resistance due to the
modulation of insulin gene expression leading to hyperinsulinemia and reduced effects of
insulin 62 E2 levels stimulate ER expression, and ERs are also implicated in insulin-like
growth factor promoters, progesterone receptor expression and tumor growth66-68. The
effects of E2 on fuel selection processes (Fig. 1) and the sexual dimorphism in response
to exercise are discussed further in section 1.6.
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Figure 2 A comparison of the relative estrogen concentration in the blood during the
menstrual and estrous cycles. The level of circulating estrogen is higher during the luteal
phase (LP) of the menstrual cycle despite the peak around day 14. In estrous, the
estrogen concentration in the blood is highest during proestrus, an approximately 12
hour phase. Proposed fuel usage of lipids (FAT) and carbohydrates (CHO) in relation to
estrogen concentration is also shown. High circulating estrogen would occur during LP
in humans and proestrus in the rat.
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1.5 Methods to Study the Estrous Cycle and T1 Diabetes
Historically, the phases of the estrous cycle were determined through observed
behavioural changes or through visual and microscopic examination of the uterine tissues
or vaginal secretions60. Vaginal cytology either through lavage or swabbing has since
been determined to be highly accurate in phase determination60,69,74,79. Multiple staining
methods may be used to interpret samples, with Papanicolaou’s stain recognized as the
optimal choice for visualizing abnormalities and detailed structure in humans, but several
other stains including standard hematoxylin and eosin stain sufficient for visualizing
structure60,77,79. A minimum of 14 consecutive samples, one per day at the same time each
day, are needed to determine the length of the cycle60. Collecting consecutive samples
avoids blind reading, or the process of attempting to read one stain without context of the
previous day’s stain which can provide inconsistent results, particularly if the timing of
the swab is during a transitional period60,77. Proestrus is characterized by round nucleated
cells that may be clumped together or may appear in strands, however the clustering does
not need to be present to recognize proestrus. Estrus shows predominantly keratinized
anucleated epithelial cells often with jagged edges, with some nucleated epithelial cells
possible. If the smear is not performed properly it is possible for the keratinized epithelial
cells to be present in other stages, as these cells are present in the lower vaginal canal60.
Neutrophils may be present in both metestrus and diestrus and are present only in low
numbers in proestrus and estrus. The metestrus phase contains roughly equal proportions
of neutrophils, nucleated and keratinized epithelial cells, with greater numbers of
nucleated cells appearing towards the end of the stage. Diestrus contains fewer
keratinized epithelial cells than metestrus, and neutrophils and nucleated epithelial cells
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present but in lower numbers than metestrus. These two stages are sometimes combined
into one due to these similarities, however they can often be distinguished by the lower
cellularity during diestrus60,76-78.
The low-dose STZ rodent model imitates the development of T1DM in humans25,
and due to the short estrous cycle, this model means that each phase of the cycle can be
examined within a four to five day span, rather than the 28-day cycle in humans. The
determination of the cycle phase through vaginal cytology is well established, and the
phases of the estrus cycle directly related to levels of sex hormones during those phases.
Therefore, staging the exercise based on these vaginal swabs should allow an
examination of the response to recurrent exercise when the lowest and highest levels of
estrogen are present.

1.6 Sexual Dimorphism in Response to Exercise
There are well established differences in hormone levels and the glucoregulatory
between males and females during multiple types of exercise. There is support for the
role of estrogen in these metabolic differences, as evidenced by studies which utilize E2
supplementation in men or postmenopausal women, or direct comparisons between LP
(high E2) and FP (low E2)51,56,57. Indeed, supplementation oral E2 has resulted in higher
lipid oxidation rates and greater carbohydrate preservation during endurance exercise,
and that under normal conditions males have a greater reliance on carbohydrates
compared to females in both LP and FP80-83. In studies using ovariectomized females, E2
supplementation spared heart, liver and muscle glycogen and increased fat oxidation
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during prolonged submaximal and maximal treadmill exercise82,83. Prior administration of
E2 to males causes a shift toward lipid utilization during an acute bout of exercise81. It
was stated that these differences in fuel selection between sexes were due to differences
in body composition and fitness levels; however, the participants were matched based on
relative VO2max. Further, the differences in glycogen sparing appear between females in
LP and FP, with LP preserving more total and muscle glycogen than both females in FP
and males, while no difference in muscle glycogen content was evident between females
in FP and males80. Aerobic exercise during the LP results in greater release of estrogen
than exercise during the FP84. The pattern of growth hormone (GH) release at rest and
during exercise is also sexually dimorphic, with females in both phases of the menstrual
cycle releasing greater GH in response to aerobic exercise and under resting
conditions84,85. Others have found that the relative increase in GH from baseline is greater
in males even though the peak level reached is greater in females, whereby this peak is
also reached faster in females than males86. Others still have found the opposite to be
true, with males having higher GH release during aerobic and resistance exercise87,88.
There is some discrepancy in the literature, and this may be due to the baseline GH
values being greater in females at baseline, or due to other differences in sex hormones.
GH, epinephrine and glucagon release during the glucose counterregulatory
response to hypoglycemia may be influenced by estrogen89-91. As detailed above, there is
a blunting effect of antecedent hypoglycemia on the counterregulatory response to
subsequent hypoglycemia41,42. There is conflicting data as to whether or not this effect is
different between the sexes, with some evidence demonstrating that estrogen reduces the
counterregulatory hormone response in females in comparison to males89. Other studies
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have demonstrated that the counterregulatory response following prior hypoglycemia is
actually worse in males and that only deeper hypoglycemia elicits any reduction in the
counterregulatory response in females90,92. Since the counterregulatory response may be
preserved in females following prior hypoglycemia, males may be at a greater risk of
subsequent hypoglycemia Exercise during the LP may also result in higher lipid
oxidation than exercise of the same type and intensity during the FP, although in human
studies these findings have been challenged as the measure to examine fuel selection in
these studies is the respiratory exchange ratio (RER)80,92. RER relates CO2 production to
O2 uptake which increases during intense exercise and is an indirect measure of fuel
source during exercise93,94. Higher RER is associated with carbohydrates as the primary
fuel source, and low RER is associated with fat as the primary fuel source. RER if used
alongside other measures of fuel selection, such as rates of glucose appearance or
disappearance, or euglycemic clamping, can be an accurate means to determine fuel
selection; however, RER is influenced by training level, dietary fat intake, ketogenesis
and muscle fiber composition93,94,95. Interestingly, RER during exercise is lower in
females than in males, indicating that the female body relies more on lipid oxidation than
carbohydrate36,38,96. When dietary intake differs significantly between the sexes, with fat
intake higher in males than females, the difference was not apparent95. Higher body fat
levels in females may be responsible for some of this effect, or higher intramyocellular
lipid (IMCL) levels which is also reported to be elevated in females97,98. While these
differences can be largely attributed to estrogen97, the increased IMCL content does not
necessarily translate into higher IMCL turnover99. The difference in RER, fuel selection
and glycogen sparing between the sexes is greater during LP than FP, suggesting that the
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higher E2 levels are partially responsible for this shift80, 96. This study proposes that the
lipid and carbohydrate usage will shift as a result of high estrogen circulation during
proestrus as shown in Figure 1. It has been suggested that intramuscular recovery is
greater during LP due to the anti-oxidant effects of E2101. In this study it was shown that
creatine kinase (CK) levels were significantly higher following aerobic exercise during
the FP than exercise during the LP. CK is a marker of damage to the cell and is present in
greater quantities following intense prolonged exercise. The properties of E2 as an antioxidant are suggested to either increase the healing process or decrease the damage
incurred during prolonged exercise101.

1.7 Rationale
This study serves to fill a gap in the literature regarding the sex dependent effects
of repetitive bouts on hypoglycemia onset during and following exercise. The
glucoregulatory response to exercise is different between the sexes, and it is possible that
estrogen is responsible (directly or indirectly) for these differences. Studies have
demonstrated that different phases of the menstrual cycle has an effect on glycogen usage
during exercise in healthy patients but have not elucidated a mechanism for this
phenomenon80,84. Females have higher lipid oxidation during exercise, less glycogen
depletion and are less effected by blunting of the counterregulatory defense against
hypoglycemia61,80. As such, females may be more protected against exercise-induced
hypoglycemia due to an E2 mediated fuel selection shift towards lipid oxidation and
quicker BG recovery. Moreover, it is possible that the protective effects may be greater
during the luteal phase when estrogen levels are at the highest.
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Aerobic exercise has been shown to decrease blood glucose and complications
associated with T1DM27,28,30,32. The risk of hypoglycemia during and after exercise is a
main factor in exercise avoidance by patients with T1DM21. Increased levels of estrogen
in healthy subjects are correlated with increased fat usage and carbohydrate sparing80-83.
The RER of exercising females in the LP and FP of the menstrual cycle is lower than the
RER of exercising males, with LP during RER lower than RER during FP. It is unknown
what role estrogen plays in female patients with T1DM and the mitigation or reduction in
hypoglycemia risk. It is plausible that T1DM females may be at less risk for
hypoglycemia during the LP phase of the menstrual cycle when estrogen levels are at
their highest.

1.8 Purpose and Hypothesis
The purpose of this study was to examine the blood glucose response to recurrent
aerobic exercise in male and female rodents with streptozotocin-induced T1DM treated
with intensive insulin therapy. We examined whether consecutive days of aerobic
exercise would result in differences in blood glucose (BG) response and liver glycogen
usage between groups. We believe that the sex hormone estrogen may provide protection
from hypoglycemic episodes in females, as estrogen shifts fuel selection toward lipid
usage and is glycogen sparing (Fig. 1). The changes in hormones throughout the
reproductive cycle have been shown to alter fuel selection and the counterregulatory
response to hypoglycemia. To do so, female animals (T1D and non-T1D) were exercised
starting during the lowest estrogen period and finishing in the highest estrogen period to
show the greatest protective effects possible and to encompass the entire estrus cycle. We

20

hypothesized that female T1DM rodents would have higher blood glucose during and
post exercise than male T1DM rodents. Secondly, we hypothesized that females T1DM
rodents would have fewer instances of exercise-induced hypoglycemia than their male
diabetic counterparts and a fuel selection shift would result in liver glycogen sparing for
the T1DM females even after four days of repetitive exercise.
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Chapter 2

2.1 Introduction
Type 1 diabetes mellitus (T1DM) is a disorder resulting from the autoimmune
mediated destruction of the beta-cells in the pancreas. These cells are insulin producing,
and their destruction results in sub-optimal or no circulating endogenous insulin. The
failure of the body to produce optimal insulin levels in the blood results in increased
blood glucose levels, leading to chronic hyperglycemia in the absence of insulin therapy
treatment. As a result, several health complications are associated with chronic
hyperglycemia including retinopathy, nephropathy, and cardiovascular disease 1-3. A
large cohort trial, The Diabetes Control and Complications Trial (DCCT) demonstrated
the importance of intensive insulin therapy in the reduction of many of these diabetes
related complications, in contrast to the more traditional conventional insulin therapy
treatment. However, intensive insulin therapy increases the risk for hypoglycemia onset
three-fold in these patients4-6. The fear of exercise-related hypoglycemia is one of the
most common barriers to attaining the recommended physical activity guidelines among
the T1DM population 7.
In studies on hypoglycemia in non-diabetics, antecedent bouts of hypoglycemia,
induced by either exercise or administering exogenous insulin, have been shown to blunt
or reduce the neuroendocrine and glucoregulatory responses to subsequent bouts of
exercise9, 10. There is a sexual dimorphism in these hormonal responses to repetitive
exercise, whereby the blunted hormonal response to subsequent exercise is more
pronounced in males9-11. These sex related differences are apparent during moderate
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intensity aerobic exercise and are not evident during more intense forms of exercise 12.
Importantly, little information is available as to the impact of antecedent or successive
bouts of exercise in females with T1DM. Indeed, it has been shown that similar hormonal
blunting effects of antecedent exercise are evident in both sexes; however, female
patients with T1DM experience a less pronounced effect than male patients. The impact
of this altered glucose regulatory hormonal response on hypoglycemia risk is not known.
Many studies investigating the sex differences in glucose hormonal responses in patients
with T1DM often maintain normal BG throughout the exercise and recovery periods;
thus, alterations in blood glucose levels in response to repetitive exercise were not
determined 9,10.
Estrogen (E2) plays a key role in maintaining glucose homeostasis in the body as
higher levels of E2 are linked with lower respiratory exchange ratio (RER) and higher
lipid oxidation 13-16. In healthy women, circulating E2 levels during the luteal phase (LP)
are highest and can be potentiated by exercise during this menstrual cycle phase 16-18.
Further, the use of oral contraceptives in males and postmenopausal females resulting in
elevated estrogen levels has also been shown to increase Free Fatty Acid (FFA) levels
during heavy aerobic exercise, suggesting an E2-mediated shift towards fat oxidation
during the exercise bout, while carbohydrate metabolism was not impaired 17,18. The
increased levels of E2 also have an impact on exercise-mediated secretion of growth
hormone (GH), a hormone that is well established to elevate hepatic glucose release
during strenuous exercise16,17,19. Further, females have higher resting GH levels than
males, and larger GH response to exercise is evident when E2 levels are highest 16,18. Due
to the lower and relatively stable E2 levels during FP compared to LP and the potential

40

metabolic influence of this hormone, studies 9,10 are often conducted during the FP when
E2 levels are the most stable and closer to (but still higher than) levels in males 9,10,12,19.
In female patients with T1DM, these apparent fuel selection differences as a result of
elevated E2 during the LP could have an impact on counterregulatory measures against
rapid reductions in blood glucose, as a shift towards lipid oxidation could be glycogen
sparing; ultimately, leading to reduced risk of hypoglycemia in female T1D pateints16,19.
The purpose of this study was to examine the sexual dimorphism in the blood
glucose response to recurrent bouts of prolonged aerobic exercise in T1D and non-T1D
rats. The menstrual cycle in humans is comprised of LP and the follicular (FP) phases,
with LP characterized by high levels of E2 and greater fluctuations of E2 than FP. To
observe the role of E2 we compared the blood glucose response to aerobic exercise over
the four day estrous cycle of the rat. Moreover, to examine the glycogen sparing effect of
E2 during recurrent exercise in female T1DM rats we examined hepatic glycogen levels
immediately after the fourth bout of exercise during the proestrus phase of the estrous
cycle, the phase shown to have the highest E2 levels. We hypothesized that fuel selection
differences would result in female T1DM and non-diabetic rats utilizing fat oxidation
over carbohydrates, resulting in a minimal change in blood glucose levels during and
following aerobic exercise that was concomitant with higher post-exercise liver glycogen
content in comparison to their male counterparts.
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2.2 Materials and Methods
2.2.1 Ethics Approval
This study was approved by the University Council of Animal Care of Western
University (London, Ontario, Canada) and conducted in accordance with the standards of
the Canadian Council on Animal Care.
2.2.2 Animals
Twenty Sprague Dawley rats (10 males, 10 females) were obtained from Charles
River Laboratories (St. Constant, Que., Canada) at 8 weeks of age. The rats were housed
in standard cages in same sex pairs until assignment to groups at which point animals were
housed in pairs with the fifth rat in each group housed singly. Rats were maintained on a

light-dark cycle of 12 h, with temperature held at 20.5C and relative humidity at 40%.
Standard rat chow and water were provided ad libitum for the duration of the study.
2.2.3 Experimental Groups
Rats were randomly assigned into one of four groups: control (non-T1DM)
exercise male (CXM, n = 5), control exercise female (CSF, n = 5), T1DM exercise male
(DXM, n = 5), and T1D exercise female (DXF, n = 5). Animals in DXM and DXF
underwent a diabetes induction protocol in the second week of the study.
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2.2.4 Experimental Design
2.2.4.1 Diabetes Induction
Animals were acclimatized for five days following transportation to the animal
facility. Following this period, T1DM groups (DXF and DXM) underwent a 5-day
protocol of intraperitoneal low dose injections of streptozotocin (STZ; Sigma-Aldrich) to
induce T1DM (week two, Fig. 3). For seven consecutive days, 20mg/kg of STZ
(dissolved in a citrate buffer; 0.1M, pH 4.5) was injected each day and was administered
within fifteen minutes of drug preparation. Diabetes was confirmed by two consecutive
days of non-fasted blood glucose concentrations greater than 18mmol/L. Once diabetes
was confirmed, insulin pellets were implanted (week three, Fig. 3) subcutaneously via
surgical incision in the abdomen of all rats (1 pellet = 2 U insulin/per day). All animals in
the diabetic groups were given one insulin pellet to begin with regardless of weight. Insulin

therapy was adjusted throughout the study by addition or removal of pellets as needed.
Blood glucose was maintained in this manner at an intended range of 4-8 mmol/L.

2.2.4.2 Exercise Protocol
One week prior to exercise (week 7) all animals underwent familiarization with
the treadmill. The familiarization process was designed to allow animals to become
acquainted with the speed of the treadmill and consisted of two days of 15 min of running
up to 27m/min for females and 20m/min for males. During the week of exercise (week
8), all animals participated in 1 hour of aerobic exercise at 9am for four consecutive days
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at approximately 75% of their maximal oxygen consumption. To account for differences
in maximal oxygen uptake and weight, the running speed for female groups was 25m/min
at 6% grade and 18m/min at 6% grade for males. Treadmill speeds were based on studies
reporting oxygen consumption values in exercising male and female rats39. While males
have higher VO2max in most situations, the weight discrepancy resulted in males
needing to exercise at a lower speed which still reflected the same percentage of absolute
VO2max. Animals were monitored during a recovery period of 60 minutes postexercise
(120 minutes from the initiation of exercise) (Fig. 2). Additionally, DXF and CXF were
staged to ensure that the final day of exercise would be during proestrus. Due to the
differing treadmill speeds DXM and CXM were exercised immediately following DXF
and CXF exercise was complete for that day. DXM and CXM were not staged based on
any hormonal fluctuations,
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Exercise Protocol, Recovery and
Sacrifice
Day 1 – Day 3
Exercise

0 min

30 min

Recovery

60 min

90 min

120 min

Day 4
Exercise

0 min

30 min

Sacrifice

60 min

65 min*

Figure 2 Exercise protocol for days 1 through 3, and day 4, respectively.
Saphenous vein blood samples were taken at all timepoints unless otherwise
indicated (*). Sacrifice was performed immediately following exercise and
tissue samples used in this study were taken within five minutes post exercise.
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Weekly Timeline
Week 1

•

Acclimatization

Week 2

•
•

STZ protocol for DX groups
Daily weigh-ins for CX groups.

Week 3-6

•
•
•

Week 7

•

Insulin pellet adjustment for DX groups
Vaginal swab protocol for DXF and CXF
Twice weekly weigh-ins and blood draws for blood glucose
concentrations
Treadmill familiarization in two separate bouts of 15 min each

Week 8

•
•
•
•

Four daily bouts of one hour of treadmill exercise at 80% VO2max
DXF and CXF staged such that the final bout of exercise occurs
during proestrus
Blood draws at 0 min, 30 min, 60 min, 90 min and 120 min
Day 4 sacrifice at 60 min via cardiac puncture under isoflurane

Figure 3 Timeline of events from week 1 through week 8. Week 1 consisted of
acclimation to environment. Week 2 consisted of streptozotocin (STZ) injections to induce
type 1 diabetes mellitus in animals assigned to diabetic female (DXF) or diabetic male
(DXM). No procedures other than weighing and blood draws occurred for control female
or control male (CXF and CXM, respectively). During week 3- week 6 insulin pellets
were implanted surgically in DXF and DXM and adjusted as needed throughout the
remaining weeks. Week 7 all animals underwent two days of familiarization with the
treadmill protocol. Week 8 all animals underwent four days of consecutive aerobic
exercise. On the final day of week 8 all animals were euthanized, and tissue samples
collected.
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2.2.5 Experimental Measures
2.2.5.1 Body Weight and Blood Glucose
Body weights and blood glucose levels were recorded weekly throughout the
study. Weekly blood samples (~50 L) were obtained via saphenous vein puncture in the
hind leg. Blood glucose was measured using the Freestyle Lite Blood Glucose
Monitoring System (Abbot Diabetes Care, INC.). During the week of exercise (week 8),
blood samples were collected prior to commencing exercise, at 30min intervals during
exercise until 60 min post-exercise via saphenous vein puncture on alternating hind legs.
Blood was collected in non-coated tubes then centrifuged at 3000rpm for 20 min at 4C.
Supernatant was obtained and stored at -80C until analysis.
2.2.5.2 Vaginal Swabs
In Week 2 and 3 of the experiment, DXF and DSF underwent daily vaginal swabs
for twelve days to determine the length of the estrus cycle. A sterile cotton swab was
dipped in saline (0.9 M) and inserted into the vagina at a 45 angle, half turned, then
remove. The swabs were then rolled horizontally onto a clean slide with firm pressure.
Animals underwent additional swabbing once per week to confirm estrus stage
prediction, including the week prior to exercise. Upon determination of the length of the
estrus cycle, females were staged such that the last day of exercise occurred during
proestrus.
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2.2.5.3 Tissue Collection
Rats were euthanized within five minutes of the final bout of exercise to allow
hepatic tissues to be examined for glycogen levels (day 4). Animals were placed under
5% isoflurane until all reflexes were absent and euthanized via cardiac puncture. Liver
tissue was obtained and frozen in liquid nitrogen, then stored at -80C until analysis.
2.2.6 Hematoxylin and Eosin Staining
Vaginal slides were dried for at least five minutes, then placed in a fixing solution
(Rapid Fixx, Shandol) for one minute (Appendix D). Slides were placed in Harris
Haematoxylin for 1 minute, then rinsed in tap water for 1 minute. Excess stain was
removed with minimal amounts of water and dehydrated in 70% ethanol for 1 minute.
Slides were submerged in 5% Eosin solution for 1 minute. Slides were rinsed again in tap
water to remove excess stain and dehydrated in ascending alcohol. Finally, slides were
cleared using xylenes and mounted using toluene-based media. Following staining slides
were examined under a Zeiss AxioVert S100 microscope at 10x magnification to
determine the phase of estrus (see Fig. 5).
2.2.7 Estrogen Quantification
Serum estrogen concentration was determined via enzyme-linked immunosorbent
assay (17 beta Estradiol ELISA Kit, Abcam). Samples were obtained from the day 1 and
day 4 pre-exercise saphenous vein blood draw (t = 0). Samples, standards, and blanks
were added to a 96-well plate precoated with anti-Estradiol IgG. 17 beta Estradiol-HRP
conjugate was added to each well. The plate was incubated for 2 hours at 37C followed
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by aspiration and washed three times. Substrate solution was added and incubated in the
dark at room temperature for 30 minutes. Immediately following the incubation period,
stop solution was added to each well in the same order as substrate solution. Absorbance
was measured at 450nM within ten minutes of adding the stop solution.
The absorbance of the sample was adjusted based on the absorbance of a blank,
and a standard curve (R = 0.97) was developed using prepared standards. The
relationship between absorbance and concentration is logarithmic, therefore an equation
was developed based on the standard curve to reflect the logarithmic relationship between
absorbance and concentration.
2.2.8 Liver Glycogen Content
2.2.8.1 Liver Homogenization
Liver samples were removed from storage at -80C and kept on ice.
Approximately 20 mg of tissue was excised from the sample and placed into a 2.0 mL
Eppendorf tube (Appendix A). Samples were submerged in 30% potassium hydroxide
solution saturated with sodium sulfate, and placed in boiling water for 30 min. Samples
were precipitated in 95% ethanol for 30 min in an ice bath, followed by centrifugation at
3000 rpm for 30 min. The supernatant was discarded, and the glycogen pellet
immediately dissolved in ddH2O.
2.2.8.2 Glycogen Quantification
Homogenized liver samples were added to a 96 well uncoated plate. A colour
reaction was developed by rapid addition of 5% phenol and 98% sulfuric acid to the
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sample. Samples were placed in a water bath (37C) for 20 min. Samples were analyzed
in triplicate at a 490 nm on a microplate reader and compared to known glycogen
standards (Appendix A).

2.2.9 Data Analysis
Liver glycogen content and blood glucose levels were compared using a threeway analysis of variance (ANOVA) with sex, time and diabetes as factors using
GraphPad Prism 8 (GraphPad Software, Inc.). Post-hoc analysis was performed using
Tukey’s multiple comparisons test when significant differences were found. Estradiol
concentration on day 1 (diestrus) and day 4 (proestrus) between the sexes was analyzed
using a two-way ANOVA and post-hoc analysis was performed using a Sidak test.
Significance was accepted at an alpha value of 0.05.
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2.3 Results
2.3.1 Animal Characteristics

Results of both body weight and blood glucose were analyzed to examine the
influence of diabetes (T1DM vs. non-T1DM), time (week of study), and sex (male vs.
female). Body weight (Fig. 4a) and blood glucose (Fig. 4b) data were collected for 19
animals (DXF n = 5, DXM n = 4, CXF n = 5, CXM n = 5). One animal from DXM was
excluded as they were unable to complete the full hour of exercise on day three. There
was a significant interaction between time and diabetes (P < 0.0001), and time, diabetes
and sex (P < 0.05). In week two of the study, DXF and DXM had higher blood glucose
levels than CXM and CXF (P < 0.0001). There was no difference in week two blood
glucose levels between DXF and DXM (P > 0.999). At week six, blood glucose levels
were significantly elevated in DXM and CXM (P < 0.05). At week eight, blood glucose
was significantly higher in DXM compared to both CXM and CXF (P < 0.05). At no
point was there a statistically significant difference in blood glucose between DXF and
DXM. The initial dosage (week 2) of insulin (ug/g) was higher in DXF (P < 0.05)
primarily due to the smaller size of the females (Fig. 6). There was no difference in
insulin dosage/gram between the groups in week 8 of the study (P > 0.99).

The body mass of DXF and CXF were significantly lower than that of DXM and
CXM (P < 0.0001). No differences in final weight (week 8) between DXM and CXM
was evident (P > 0.05) and DXF and CXF (P > 0.05). The effects of sex and week were
statistically significant on weight (P < 0.0001) while diabetes was not (P > 0.05)
statistically different. There was an interaction between time and diabetes (P < 0.01), time
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and sex (P < 0.0001), diabetes and sex (P < 0.0001), and time, diabetes and sex.
(P < 0.0001).

2.3.2 Vaginal Swabs

Representative vaginal images of each estrous stage are shown in Figure 5.
Proestrus (Fig. 5a) shows nucleated cells that present in clumps or sheets. Estrus (Fig.
5b) shows an abundance of keratinized, denucleated epithelial cells. Metestrus (Fig. 5c)
and diestrus (Fig. 5d) both show some nucleated cells and neutrophils, with metestrus
showing higher cellularity than diestrus. Slides were stained using a standard
hematoxylin and eosin protocol and examined against known examples of the stages of
estrous for neutrophil content, the presence and number of keratinized cells, and the
presence of mucus among other indicators.

2.3.3 Blood Glucose Response to Exercise

Results from the first three days (estrus, metestrus and diestrus) of exercise are
presented together due to the lower E2 levels observed during these days (Fig. 7). There
was a significant effect of time (P < 0.05) and a significant interaction between time and
diabetes (P < 0.0001). Pre-exercise blood glucose (BG) levels in CXM were significantly
lower in comparison to 30, 60, and 90 minutes (P < 0.05), but BG returned to normal
resting BG by 120 minutes. A slightly different pattern was observed in the CXF group.
CXF BG levels were higher (P < 0.05) during exercise (at 30 and 60 minutes) than preexercise blood glucose levels; however, the BG was normalized by 90 minutes and
maintained until 120 minutes post exercise. There was a trend towards a decrease in BG
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values from the pre-exercise levels to 30 minutes of exercise until the completion of
exercise (60 minute) but this change did not reach the level of significance. (P > 0.05 and
P > 0.05 respectively). At 30 and 60 minutes of exercise, blood glucose in DXF was
significantly lower (P < 0.05) than the CXF counterparts but no difference in BG levels
between DXF and CXF were detected at 90 minutes (P > 0.05). The DXF blood glucose
levels at 90 minutes were significantly lower (P < 0.05) than the final blood glucose at
120 minutes (60 minutes post exercise). Additionally, the final recovery blood glucose at
120 minutes in DXF was significantly higher (P < 0.05) than the 120 minutes CXF blood
glucose. There was a main effect of time (P < 0.0001) and interactions between time and
diabetes (P < 0.0001) and time, diabetes and sex (P < 0.0001)

Day 4 BG levels were obtained at pre-exercise (0 min) and 30 and 60 minutes of
exercise (Fig. 8 ). After 30 minutes of exercise, both DXF and DXM were significantly
lower (P < 0.05) than their control counterparts (CXF and CXM). However, these values
returned to baseline by the end of the exercise (60 minutes). There were no differences in
blood glucose between groups at 60 minutes (P > 0.05). There was a main effect of time
(P < 0.05) and an interaction between time and diabetes (P < 0.0001).

2.3.4 Estrogen Concentration

Estrogen concentrations measured using ELISA are shown in Figure 9. There was
a significant effect of time and an interaction between time and sex (P < 0.05). Blood
serum was obtained from day 1 and day 4 of exercise prior to exercise (t = 0). As
confirmed by vaginal cytology, day 1 serum was obtained during estrus, and day 4 serum
was obtained during proestrus. Day 4 DXF had significantly higher estrogen than both
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day 1 DXF and day 4 DXM. There was no difference in estrogen concentration on day 1
between DXF and DXM (P > 0.5). Day 1 and day 4 estrogen concentration was not
different in DXM (P > 0.5).

2.3.5 Liver Glycogen Content

Liver samples were taken immediately following the final bout of exercise on the
fourth day. There was a main effect of diabetes (P < 000.1). There was no interaction
between sex and diabetes (P > 0.05) (Fig. 10). There was no difference in liver glycogen
between CXF and CXM (P > 0.05) or between DXF and DXM (P > 0.999). Liver
glycogen was significantly lower in DXF compared to CXF (P < 0.0001). DXM also had
significantly lower liver glycogen content than CXM (P < 0.0038).
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Figure 4 (a)Mean non-fasted blood glucose (mM). All data are presented as mean  SEM.
* denotes significant difference between diabetic males (DXM) and control males (CXM)
(P < 0.05), ** denotes diabetic females (DXF) significantly different than control females
(CXF) (P < 0.05).
(b) Mean body mass (g). All data are presented as mean  SEM. * denotes P < 0.05.
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Figure 5 Vaginal smears of (a) proestrus, (b) estrus, (c)metestrus and (d) diestrus.
Nucleated epithelial cells (white triangle) and clumping are present in proestrus.
Keratinized epithelial cells (black triangles) are predominant in estrus. Neutrophils
(circled) are highly present in diestrus.
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Figure 6 Weekly insulin dose comparison between week 2 (diabetes
induction) and week 8 (exercise and sacrifice). Initial insulin dose was
significantly greater in the diabetic female group (DXF) (* denotes
significance at P < 0.05) due to the weight difference between DXF and
diabetic males (DXM). By week 8 insulin dose was comparable between
the two groups.
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Figure 7 Mean blood glucose data (mmol/L) from days 1-3 are presented
together. All data are presented as mean  SEM. * denotes significance.
(P < 0.0001) between diabetic and control females (DXF and CXF,
respectively). i denotes significance within control males (CXM) (P <
0.0001) and ii denotes significance within CXF (P < 0.01). iii denotes
significance within DXF (P < 0.05). DXM (diabetic males) had no
significant changes or differences.
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Figure 8 Mean blood glucose (mM) from day 4 exercise. All data are presented as
mean  SEM. * denoted significance at t = 30 minutes (P < 0.05), ** denotes
significance (P < 0.05) between starting and ending blood glucose in control
females and males (CXF and CXM, respectively) *** denotes significance (P <
0.05) between 30 to 60 minutes in diabetic females (DXF). There were no
differences in blood glucose between CXM and diabetic males (DXM).
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Figure 9 Serum estrogen (pg/mL) from pre and post exercise protocol
between DXM (diabetic exercised males) and DXF (diabetic exercised
females). All data are presented as mean  SEM. * denotes P < 0.05.
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Figure 10 Liver glycogen content (umol/g tissue) from tissue collection on day
four following the final bout of exercise for control exercise and diabetic
exercise (CX and DX, respectively) males and females. All data are presented as
mean  SEM. * denotes P < 0.05, ** denotes P < 0.0001.
z
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2.4 Discussion
Diabetes research has evolved since the DCCT to recognize the benefits of
aerobic exercise for the individual with type 1 diabetes. However, much of the research
continues to focus on male subjects, and studies that do utilize female subjects, typically
use physiological states in which these individuals demonstrate low hormonal levels (FP)
or are experimentally regulated9,10,12,17-18. Estrogen is known to impact the progression
and risk factors associated with many other diseases, yet few studies have investigated
the effect of estrogen on the metabolic complications associated with T1DM. Indeed,
estrogen levels are correlated with a shift in fuel usage towards higher fat oxidation, and
therefore may be protective to female athletes with T1DM. As such, this study aimed to
examine if the blood glucose response to repetitive exercise would differ between male
and female non-T1DM and T1DM rodents, and if this response would differ with respect
to the different phases of the estrous cycle whereby estrogen levels fluctuate throughout.
This study also resulted in a model for staging female rats for exercise studies to examine
the role of estrogen in multiple pathways and disease models.

The DXF response to exercise during days 1-3 differed in comparison to the CXF
group (Fig. 7). During exercise in CXF, the glucose counterregulatory response to
exercise was evident and blood glucose was increased in comparison to pre-exercise
levels. During the recovery period, the blood glucose levels returned to baseline levels by
120 minutes. DXF on the other hand had a drop in blood glucose from pre-exercise to 30
minutes of exercise, and a gradual recovery from 60 to 120 minutes during the post
exercise recovery. The change in DXF BG from 0 to 30 minutes was not significantly
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different; however, by 30 minutes and again at 60 minutes the difference in BG between
DXF and CXF group was statistically significant. Interestingly, the return to pre-exercise
blood glucose was faster in DXF than that observed in the CXF group. CXM had a
significant change in BG from pre exercise to 30 minutes, with an increase in BG levels.
This response was not evident in the DXM group, with there being no significant change
from 0 to 30 minutes in BG. There were no significant differences at any of the
timepoints between DXM and CXM; however, the pattern of BG response appeared
different when graphed (Fig. 7). There were no differences between the DXF and DXM
or CXF and CXM at any timepoint within the first three days of exercise. The BG
response was the same between the sexes, and the variation was primarily caused due to
time and the interaction between time and diabetes. It is possible that the BG levels and
response were similar due to fuel selection similarities between the sexes due to similar,
stable E2 levels16-19. Previous studies from our lab have shown that aerobic exercise
causes a decrease in BG in male diabetic rats as would be observed in an insulin treated
type 1 diabetic male athlete undergoing exercise 20,21.

We hypothesized that BG levels in female T1DM rats during the final bout of
exercise (day 4) would remain optimal due to increased levels of estrogen in the proestrus
stage of estrous. This would be evident through an increased level of liver glycogen
content due to the glycogen sparing effects of estrogen and the preferred utilization of fat.
The DXF had significantly lower BG response at 30 minutes compared to CXF, which
was similar to the response in days 1-3, suggesting there was still high glucose use
despite higher E2 levels than the day before. The DXF BG was not different at any
timepoint than DXM. CXM and CXF also did not differ in BG response at any timepoint
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during day 4 (Fig. 8). Both CXM and CXF saw a significant increase in BG from starting
to ending BG which may have been consistent with results from day 1-3 and
representative of normal BG response to aerobic exercise36, 37. As show in Figure 7, the,
BG during the first three days of exercise in the DXF and DXM groups dropped
significantly from 0 to 30 minutes, while BG in the CXF and CXM groups increased
significantly from baseline. While these data do not support our hypothesis suggesting a
glycogen sparing role for estrogen during day 4 of exercise, it is plausible that the
previous bouts of exercise stressed the glucoregulatory response system of DXF rodents
such that the glucose sparing effects of estrogen were mitigated. The DXF group was the
only group that had a post-exercise day 1-3 BG higher than that during exercise (t =
30min, 60min). DXF BG was also higher at 120 minutes than it was at 90 minutes (Fig.
7). It is possible that the hormonal differences between DXM and DXF resulted in greater
fat oxidation during the exercise period, allowing the DXF group to return to resting BG
levels faster than their male counterparts. E2 mediated shift in fuel selection (Fig. 1)
towards fat during aerobic exercise protects against liver glycogen depletion and
therefore smaller post exercise glucose uptake, resulting in BG leveling out faster in
females19,38. The exercise intensity (approximately 75%) chosen for this study taxes
glucose homeostasis as higher intensities primarily utilize stored carbohydrate for energy.
The post-exercise period following exercise of such an intensity is when people with
T1DM face the greatest risk of hypoglycemia as the body attempts to reestablish glucose
homeostasis, and in males the greater reliance on carbohydrates during exercise and
during recovery relative to females puts them at greater risk for post-exercise
hypoglycemia 34.
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Comparisons of day 1-3 and day 4 were not directly performed due to the
differences in blood collection due to the sacrifice procedure, however we observed that
there appeared to be an increase in all groups of BG at 60 minutes on day 4 (Fig. 8). This
pattern is not typical of the recovery to aerobic exercise, nor is what was observed on
day1-3 21. It is possible that this increase in BG during the final blood draw was due to
the sacrifice procedure itself. The use of isoflurane as an anesthetic has been linked to
increases in BG in human surgical patients, but it is unclear if the amount of isoflurane
administered could have had such an immediate effect on BG levels 22. Blood draw
techniques which are animal sparing such as tail or saphenous vein draw are considered
less stressful to the animal, however serial draws may be more stressful resulting in
systemic changes in GH, BG, and epinephrine levels 22, 23. It is possible that the serial
blood draws coupled with the level of anesthesia administered to the animal the final
blood glucose reading is inflated, but not to a level of significance. Exercise type and
reinforcement methods have been noted to influence the stress and estrogen response to
exercise; however, the methods used in this study (i.e. treadmill running and air pressure)
have the smallest effect on these measures 24.

Weekly blood glucose levels (Fig. 4a) were as expected for control groups and
remained stable throughout the 8 week period leading up to exercise. During week two of
the study there was an increase in blood glucose concomitant with the low dose STZ
protocol for diabetes induction, and a subsequent decrease in blood glucose following
insulin pellet implantation (Fig. 6). In the final weeks of the study there was an increase
in blood glucose in DXM relative to the other groups, and this increased blood glucose
was not responsive to additional exogenous insulin. This change in blood glucose did not
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reach the level of significance likely due to the small group size of DXM (n = 4) due to
the exclusion of one animal from the study. The animal was excluded as it was unable to
complete the full hour of exercise at the required intensity on day 3 of the study. Despite
not reaching the level of significance, the elevated blood glucose is worth discussing
further and may highlight some sex differences in glucose control during long term
intensive insulin therapy. While there were no direct measures of insulin resistance, it is
reasonable to propose that the DXM cohort became resistant to insulin as evidenced by
daily glucose levels outside of the target range (4-7 mM). Hyperinsulinemia may have
elicited insulin resistance development through a mechanism of oxidative stress and may
further impair the body’s insulin sensitivity response during exercise 25, 26. The level of
insulin in the DXM group was appropriate for the weight and size of the animals, and no
such effect was seen in the female cohort who received the same amount of insulin
relative to body size (Fig. 6).

Sample vaginal smears taken during the fourteen day swabbing protocol are
shown in Figure 5. We were able to successfully identify the four stages of estrous in all
female rats by examining the smear in its entirety and comparing the presence of
neutrophils, keratinized epithelial cells, and nucleated epithelial cells 23. Serum estrogen
levels confirmed that the prediction method used resulted in accurate staging of the
exercise. Day 4 estrogen levels were significantly higher than day 1 levels in females, and
day 1 levels were not significantly different than male levels. Therefore, we believe that
this method can be used to stage animals based on corresponding estrogen levels. This
method involved two weeks of daily swabs to establish cycle length for each rodent, and
confirmation of the predicted stage prior to experimentation. This method avoids blind
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swabbing by establishing the initial cycle length, which prevented erroneous staging 27.
Experimental protocols were carried out in the morning as the changes throughout the
cycle tend to occur at the same time each day, and it has been suggested that the
swabbing in the morning presents the best chance of seeing all four stages27, 28. While
various external factors including housing male and females rats in the same room have
been said to induce synchronization of the estrous cycle in rodents 29 we did not find this
to be the case. Melatonin release and light-dark cycles may also affect the cycle;
however, the rats in question were on a controlled light dark schedule which has been
shown to mitigate fluctuations in the estrus cycle30. The estrous cycles of all female rats
in this study were four days in length, consisted of all four phases (Fig. 5), and did not
synchronize or appear to change based on environmental or experimental conditions.

We hypothesized that by performing the final bout of exercise during proestrus
stage liver glycogen would be spared in both DXF and CXF compared to DXM and
CXM; however, we found no differences between the sexes in liver glycogen content
(Fig. 10). The only significant factor in liver glycogen content was diabetes, which was
to be expected in males based on previous literature from our laboratory20,21,37. The
proposed fuel usage shift in Figure 1 would suggest that the higher lipid usage would
spare liver glycogen and therefore better protect DXF and CXF against exercise induced
hypoglycemia. The absence of a glycogen sparing effect in females is in contrast to data
showing lower glycogen usage in healthy exercising women in the LP 16 due to the higher
estrogen levels. Further, it has been shown that females have a greater FFA level than
males due to the fuel selection shift towards fat oxidation that is linked to estrogen 16, 19.
It is possible that due to the previous days of exercise the cumulative blunting effect on
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DXF during low estrogen levels (metestrus, diestrus and estrus) created a reduced
lipolytic response. The BG response between males and females in this study were the
same in both diabetic and non-diabetic groups in spite of the similar reduction in liver
glycogen, suggesting that the blunting effects on the counterregulatory system seen in
females in other studies were mitigated in this group, potentially due to the higher
presence of estrogen.8, 10, 32. Potential differences in muscle glycogen usage were not
examined in this study and should be investigated in the future.

2.5 Conclusion
In conclusion, this study contributes to addressing the lack of literature regarding
the effect of repetitive aerobic exercise on the glucoregulatory response to exercise in a
male and female type 1 diabetic rat model. We hypothesized that female diabetic rodents
would have higher BG throughout the four days of exercise than their male diabetic
counterparts, and that this response in the female diabetic rodents would closely resemble
the female controls. We also hypothesized that staging the exercise such that the final
bout would occur during the period with the highest estrogen levels would contribute to
maintaining BG throughout the prolonged exercise. Finally, we expected the liver
glycogen content to be preserved in the female diabetic rodents due to the fuel selection
differences that are observed between the sexes.
The current study presents a model for future research into the sexual dimorphism
in healthy or diseased rodent models for studies that may be affected by fluctuations in
female sex hormones. The use of vaginal cytology to determine the estrous phase is not a
new technique; however, the application of this technique to provide a schedule for an
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experimental protocol dependent upon estrogen level is to our knowledge a new
technique that spares blood volume that can otherwise be used for other testing. The
ability to detect the presence and quantity of cells in the smear is paramount to the
accuracy of the staging, and therefore consecutive swabs should be taken for a sufficient
period before making staging predictions.
There were no apparent differences in liver glycogen content between the male
and female T1DM rats. However, there was a greater post-exercise blood glucose
recovery in the DXF, suggesting that while there was a decrease in blood glucose during
exercise the DXF group was able to counteract this effect more successfully than DXM.
The DXM group may have needed longer to reach the resting blood glucose levels. It is
possible that the increase in estrogen due to the staging of the exercise had an effect on
the fuel selection during exercise or recovery although the mechanism of this cannot be
elucidated from this study.
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Appendices
Appendix A: Phenol-Sulfuric Acid Assay for Glycogen Quantification
Part A: Solutions
30% KOH (w/v)
•
•
•

30 g of KOH pellets
100 mL of ddH2O
EXOTHERMIC REACTION — combine in an Erlenmeyer flask placed in an ice
bath

95% Ethanol (v/v)
•
•

95 mL of 100% Ethanol
5 mL of ddH2O

Glycogen Standards: 0.1, 0.2, 0.3, 0.4, 0.5 and 0.6 mg/mL
•
•

1

Prepare large volumes of standards and store in 15 mL Falcon Tubes
Standard curve flattens out after 0.6 mg/mL (see below)1
o Linear portion spans from 0 to 0.5 or 0.6 mg/mL

With a 5% (w/v) Phenol solution, the standard curve was linear from 0.0 – 1.0 mg/mL glycogen
concentrations with an R2 = 0.99.
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100% Sulfuric Acid (Stock)
5% Phenol (v/v)
•
•

5 mL of 100% phenol (stock)
95 mL of ddH2O

Part B: Tissue Homogenization and Glycogen Isolation
1. Cut and weigh approximately 20 mg of tissue, place into a 2.0 mL Eppendorf tube
and keep on ice until the next step.
2. For 12 samples, saturated ~10 mL of 30% (w/v) KOH solution with Na2SO4.
3. Boil approximately 0.75 L of water and pour into the metal tray on the hot plate. Set
the hot plate to MAX.
4. Add 500 µL of the Na2SO4-saturated KOH solution to each Eppendorf tube, ensuring
that each sample is completely submerged.
5. Place samples in a boiling water bath for 30 minutes. Half way through, agitate the
tubes until no pieces of tissue are visible.
6. Place tubes on ice and precipitate glycogen by adding 1 mL of 95% ethanol for 30
minutes.
7. Centrifuge tubes at 3000 rpm for 30 minutes.
8. Discard the supernatant and immediately dissolve the pellet in 1 mL of ddH2O.
a. Do NOT allow the pellet to dry
Part C: Glycogen Quantification
1. Turn on the hot water bath and set it to ~70 °C.
2. In a flat-bottom polystyrene 96-well microplate, pipette 50 uL aliquots of ddH2O,
glycogen standards and sample glycogen solutions in triplicate.
3. Add 150 µL of sulfuric acid to each well.
4. Quickly add 30 µL of 5% phenol to each well.
a. Works best with a repeater pipette. Use a 5 mL CombiTip set to 150 µL for
the sulfuric acid, and a 0.5 or 1.0 mL CombiTip set to 30 µL for phenol.
5. Cover plate in ParaFilm and place in a static hot water bath for 10 minutes.
6. Dry the microplate with KimWipes and measure absorbance using a microplate
reader at 490 nm (1.0 seconds).
7. Calculate glycogen concentration (units: µmol of glycogen/g of tissue):

Where:
A490 = Adjusted Absorbance at 490 nm (Sample Absorbance – Blank Absorbance)
k = slope of the standard curve (units µg-1)
W = mass of tissue sample used
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MMGlycogen = molar mass of glycogen (666.5777 g/mol)
Materials
• Microplate reader
• Centrifuge
• 2.0 mL microcentrifuge tubes
• Flat bottom polystyrene 96-well microplate
• Glass plate, razor blade, tweezers
• Eppendorf tube rack
• Metal tray and hot plate
• Kettle
• Repeater pipette with 5.0 mL and 0.5 or 1.0 mL CombiTips (optional, but
recommended)
• Static hot water bath
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Appendix B: Multiple Low-dose Streptozotocin Induction
PURPOSE: To induce Type I diabetes in rats
MATERIALS: Gloves Lab Coat Streptozotocin (STZ) 5X Stock Citric Acid/Citrate
Buffer - Anhydrous Citric Acid - Sodium Citrate Dihydrate - MilliQ Deionized Water
13M HCl 3 Falcon Tubes Sterile Filter
EQUIPMENT: Biological Safety Cabinet Weigh Scale pH Meter
PROCEDURE:
Preparing 5X Citric Acid/Citrate Buffer
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add:
a. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate b.
23.8g Sodium Citrate Dihydrate (Sigma), Mix into...
c. 175mL of MilliQ water The pH should be at 4.6, Add HCl or NaOH to
adjust (do not over-shoot pH)
2. Once the proper pH is obtained, add MilliQ water until you are close to the 200
ml mark (pH will move slightly). If satisfied with the pH, adjust volume in a 250
ml graduated cylinder and filter in a 0.2μm filter.
3. Store at room temperature. This is your 5X stock solution.
Making up Streptozotocin (STZ) for Injection *Animals should be pre-weighed prior to
making up STZ to ensure accurate amounts of STZ to be prepared.
1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL
of distilled water filtered through a 0.2μm syringe filter. Check the pH. This gives
you a working concentration of 153 mM
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2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of
concentrated HCl to the buffer, checking pH in between until desired pH is
reached. 3. Once pH is reached, add 1 mL distilled water (sterile filtered through a
0.2μm syringe filter as before). If pH is below 4.5, restart. 4. Weigh out an
appropriate amount of STZ for the number of animals (see calculations below)
that will be injected in a 15-minute time frame. Ex. Rats will be injected at
20mg/kg, so for 10 animals at an ideal weight of 200g (avg. weight of rats to be
injected), you will require a minimum of 40mg. 20mg/kg X 0.2kg = 4mg per
animal
3. The amount of STZ weighed out should be more than the minimum as some
solution will be lost in filtering. (4mg (per animal) X 12 rats = 48mg total
(0.048g) 5. Dissolve the STZ into buffer (keeping in mind a comfortable injection
volume). Shake to dissolve powder (approx. 1min). Sterile filter using a 0.2μm
syringe filter. Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution 4mg ÷ 16mg/mL
solution = 0.25mL 6. STZ is time dependent and must be used within 15 minutes
4. Injecting and Follow-Up of the Animals 1. Promptly inject each rat with the
solution (intraperitoneal) at a dosage rate of 20mg/mL (in this example, 0.25mL).
Do not use anymore STZ solution more than 15 minutes after it has been
dissolved in the sodium citrate buffer. 2. Dispose of any container having come
into contact with the STZ (in either powder or dissolved form) into a
biohazardous waste receptacle. Dispose of needles into a sharps container. 3.
Return injected rats to their cage. Record the date of STZ injection and add a
biohazard label to the cage (leave biohazard label on cage for at least 3 days
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following the last injection). 4. Repeat this procedure the following day. 5. Check
blood glucose daily. Diabetes is achieved with two non-fasting blood glucose
readings of >18 mmol Diabetes should be achieved after 5-8 injections (i.p.
20mg/kg).

REFERENCES: Low dose STZ induction protocol. Animal Models of Diabetic
Complications Consortium AMDCC Protocols. 2003
O’Brien BA, Harmon B V, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for
the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178:
176–181, 1996.
Melling CWJ, Grisé KN, Hasilo CP, Fier B, Milne KJ, Karmazyn M, Noble EG. A model
of poorly controlled type 1 diabetes mellitus and its treatment with aerobic exercise
training. Diabetes Metab 39: 226–235, 2013.
Appendix C: Insulin Pellet Implantation
Pellet implantation (for a rat):
1. Anesthetize the animal using the isoflurane machine by placing it in the induction
chamber. Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open the
stopcock valve so gas reaches the chamber. Keep in chamber until the animal is
unconscious.
2. Remove the animal and place its nose in the nose cone, reduce the isoflurane to
3% to maintain the plane of anesthesia.
3. Shave the area where the pellet is to be implanted.
4. Using gauze (or a swab), apply 10% povidone-iodine solution to the skin,
followed by 70% ethanol, to disinfect the site of insertion.
5. Hold the skin with forceps and make a subcutaneous incision.
6. Cleanse a 12g trocar with 10% povidone-iodine solution and insert it through the

80

puncture site at least 2 cm horizontally from the incision site.
7. Using forceps, briefly immerse the pellet in 10% povidone-iodine solution, rinse
with saline and insert into the subcutaneous region.
8. Use 1 pellet for up to qthe first 350g of body weight.
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 %
povidone-iodine solution over the opening.
10. Close the incision by suturing.
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
12. Record on the cage card that insulin pellets have been implanted.
Pellet removal:
1. Anesthetize the animal as described above for implantation.
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by
applying 10% povidone-iodine solution followed by 70% ethanol.
3. Using a scalpel (or scissors), make an incision through the skin superficial to the
location of the pellets.
4. Using forceps, remove the pellet. Some connective tissue may need to be cut
away using scissors. Discard the pellet.
5. Close the incision by suturing.
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
7. Record on the cage card that the pellets have been removed.
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Appendix D: Hematoxylin & Eosin
•

•
•

•

Alkaline Tap water substitute
o 0.35g sodium bicarbonate
o 2.0g magnesium sulphate
o 100mL distilled water
Harris Haematoxylin (prepared commercially)
Acid Alcohol
o 1% HCL – 5mL
o 70% EtOH
▪ 346.5 mL EtOH
▪ 148.5 mL H2O
1% Eosin Solution - stock

Procedure
1.
2.
3.
4.

Allow samples to dry for > 5 min
Place samples in Rapid Fixx for 1 minute
Hematoxylin for 20 min
Scott’s Tap water substitute – sections should end up purple blue
a. Rinse 5x
b. Fill for 1 min
c. Rinse 5x
5. Acid Alcohol 10 sec – sections should be reddish colour
6. Scott’s Tap water - sections should end up purple blue
a. Rinse 5x
b. Fill for 1 min
c. Rinse 5x
7. Eosin 3 min
8. Rinse with tap water 10-15 times to wash off surplus stain
9. Dehydrate
a. 65% EtOH 2 min
b. 80% EtOH 2 min
c. 95% EtOH 2 min
d. Anhydrous EtOH 2 min
e. Xylenes 1 min
10. Mount with toluene-based mounting media
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Appendix E: Animal Use Protocol Approval
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